Table 2 Correlation of RAD21 expression with clinicopathologic features (n = 94)
| Â | RAD21 negative | RAD21 positive | P value |
|---|---|---|---|
Age | Â | Â | Â |
≤ 50 years | 40 (70%) | 24 (65%) | 0.589 |
> 50 years | 17 (30%) | 13 (35%) | Â |
Tumor size | Â | Â | Â |
< 20 mm | 29 (55%) | 20 (59%) | 0.706 |
> 20 mm | 24 (45%) | 14 (41%) | Â |
Nodal status | Â | Â | Â |
Negative | 42 (74%) | 28 (76%) | 0.829 |
Positive | 15 (26%) | 9 (24%) | Â |
Grade | Â | Â | Â |
I | 2 (5%) | 1 (3%) | 0.128 |
II | 7 (16%) | 13 (36%) | Â |
III | 34 (79%) | 22 (61%) | Â |
ERα |  |  |  |
Negative | 22 (44%) | 17 (49%) | 0.677 |
Positive | 28 (56%) | 18 (51%) | Â |
HER2 status | Â | Â | Â |
Negative | 46 (96%) | 30 (91%) | 0.366 |
Positive | 2 (4%) | 3 (9%) | Â |
Relapse | Â | Â | Â |
Negative | 44 (79%) | 18 (51%) | 0.007 |
Positive | 12 (21%) | 17 (49%) | Â |
BCSS | Â | Â | Â |
Negative | 45 (80%) | 19 (54%) | 0.006 |
Positive | 11 (20%) | 16 (46%) | Â |